Hormone Therapy News

COVID-19 may increase the risk for blot clots in women who are pregnant or taking estrogen with birth control or hormone therapy, and more research is needed on the underlying mechanisms that could potentially drive risk, researchers wrote.

There are many ways in which women’s CV risk differs from that of men, and addressing it requires solutions tailored to women, according to a presentation at the virtual American Society for Preventive Cardiology Congress on CVD Prevention.

Cardiologists should consider a woman’s menopause status when assessing their CV risk, according to a presentation at the virtual American Society for Preventive Cardiology Congress on CVD Prevention.

Women’s health advocates discussed the potential health consequences of a Supreme Court decision to remand a case providing women with free contraception access back to a lower court.

Healio and Endocrine Today have compiled a list of the most read news from the virtual American Diabetes Association Scientific Sessions.

One-third of a cohort of men with type 2 diabetes and hypogonadism who received testosterone undecanoate therapy experienced a sustained remission of their diabetes, according to findings from a single-center study.

Children with growth hormone deficiency assigned long-acting recombinant GH therapy experienced an increase in height velocity similar to children assigned daily injections, study data show.

In May, Healio readers were interested in sex hormones being investigated for treating COVID-19, greater COVID-19 complications for patients with diabetes and obesity, associations between thyroid dysfunction and working hours, and more.

A small cohort of adolescents and young adults who identify as transgender reported limited baseline knowledge of reproduction and expressed underlying reproductive concerns that may manifest as disinterest in becoming a parent, according to findings from a pilot study published in Transgender Health.

Of the many complications reported to accompany COVID-19, one of the most vexing to researchers has been the “cytokine storm,” or the body’s overactive immune response to a viral infection. The phenomenon — observed in some patients, but not others — can complicate clinical decision-making during a time when there are no treatments and no vaccine. Researchers are searching for possible therapies that may inhibit inflammation, such as the sex hormone progesterone.